ClinicalTrials.gg
RecruitingNCT05705674Updated Mar 12, 2024

The Natural History Study of Patients With Sanfilippo Disease(s) (MPS3)

An observational study in Sanfilippo Syndrome and MPS3, sponsored by Lysosomal and Rare Disorders Research and Treatment Center, Inc.. Recruiting at 1 site in United States. Open to participants aged 5 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-03-12.

Sponsored by Lysosomal and Rare Disorders Research and Treatment Center, Inc. · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
6
Ages
5 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Mucopolysaccharidosis III with a site in United States — 12 open to participants now, 15 under way, 4 of them phase 3. Mucopolysaccharidosis III · United States.

Planned enrollment
18th of 19
6 · median 30
Started
2023
with 2 others
Observational
19 of 43
5 open now
Primary completion
2024-12
later than 0 of 14 live
Registered
35th of 43
by date

Among the 43 studies in Mucopolysaccharidosis III with a site in United States, this one is the 18th largest by planned enrollment of the 19 observational ones that give a count, is one of 3 that started in 2023, is one of 19 observational ones, reaches primary completion later than 0 of the 14 other live ones, and was the 35th registered.

Mucopolysaccharidosis III

58 studies on the registry are indexed under Mucopolysaccharidosis III; 16 are open to participants now.

Browse Mucopolysaccharidosis III studies →

Open to participants now

12 of the 43 studies in Mucopolysaccharidosis III with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Mucopolysaccharidosis III studies recruiting now, 5 set no upper age limit and 1 stops at 75 or younger; 7 take children under 18; none take healthy volunteers.

This study: 5 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Mucopolysaccharidosis III with a site in United States, or all of them as a file.
02

Study summary

The natural history study of patients with Sanfilippo disease(s) (MPS3)

Read the detailed description

This is a natural history study of patients with Sanfilippo Disease (MPS3). Patients will be followed over the course of 6 months in which they have blood and urine collected, hearing assessment, complete questionnaires and are evaluated by the Principal Investigator.

03

Conditions studied

  • Sanfilippo Syndrome
  • MPS3
04

Who can participate

Ages eligible
5 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All patients with MPS3 who meet the criteria above can be enrolled.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. IRB - approved /assent signed by subject and/or parent(s) or legal guardian(s).
  2. Genetically confirmed diagnosis of MPS III disease Genomic DNA analysis demonstrating a homozygous or compound heterozygous pathogenic variants in SGSH (type A), NAGLU (type B), HGSNAT (type C), or N- acetylglucosamine-6-sulfatase GNS (type D).
  3. Male or female; five years of age and older
  4. Negative urine pregnancy test at screening for female subjects with

Exclusion criteria

Exclusion Criteria:

  1. Unwilling or unable to follow protocol requirements as per principal investigator
  2. Any serious or chronic medical illness, including significant cardiac or severe debilitating pulmonary disease as determined by the investigator.
  3. Any medical condition that, in the opinion of the PI, would place a subject at undue risk
  4. Inability to cooperate for clinical and safety data collection
  5. Use of genistein or Miglustat within one week of the study
  6. Evidence of or infection upon serological testing at screening
  7. Currently participating in another interventional drug trial or has completed an interventional trial less than one month prior to the screening visit
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
6 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. To characterize the disease natural history in patients with MPS3.

    To characterize the disease natural history in patients with MPS3.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • LDRTC
    Fairfax, Virginia 22030, United States
    Recruiting
    • Ozlem Goker-Alpan, MD · Contactogokar-alpan@ldrtc.org · 703-261-6220
    • Lauren Noll · Contactlnoll@ldrtc.org · 571-732-4655
    • Ozlem Goker-Alpan, MD · Principal investigator
    • Lia Van, NP-C · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — No plan to make IPD available to other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2023 (actual). Primary completion is estimated for Dec 2024, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2023
First posted
Jan 31, 2023
StartActual
May 1, 2023
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Mar 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05705674
Lead sponsor
Lysosomal and Rare Disorders Research and Treatment Center, Inc.
Collaborators
Team Sanfilippo
Responsible party
Sponsor
First posted
Jan 31, 2023
Start date
May 1, 2023
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Mar 12, 2024

Study contacts

Arooj Agha
Contact
aagha@ldrtc.org
571-732-4575
Lauren Noll
Contact
lnoll@ldrtc.org
571-732-4655

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion